Concepedia

M.F. Alvisi

MA

Statistics

Publications

12

Citations

412

H-Index

10

Active since

2013

Affiliations

Mario Negri Institute for Pharmacological Research(Current)

University of Milan

Fondazione IRCCS Istituto Nazionale dei Tumori

European Institute of Oncology

Istituti di Ricovero e Cura a Carattere Scientifico

M.F. Alvisi is an author at Mario Negri Institute for Pharmacological Research specializing in medicine, oncology, and ovarian cancer.

ORCID

Publications per year

2013–2024

12

Publications

12

Predictors of Health-related Quality of Life and Adjustment to Prostate Cancer During Active Surveillance

Lara Bellardita, T. Rancati, M.F. Alvisi et al. · European Urology · 2013 · 90 citations

, , +15

Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer

Nicoletta Colombo, Federica Tomao, Pierluigi Benedetti Panici et al. · Gynecologic Oncology · 2022 · 69 citations · Full text

, , +16

High-dose ivermectin for early treatment of COVID-19 (COVER study): a randomised, double-blind, multicentre, phase II, dose-finding, proof-of-concept clinical trial

Dora Buonfrate, Fabio Chesini, Davide Martini et al. · International Journal of Antimicrobial Agents · 2022 · 58 citations · Full text

, , +15

Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenografts

Federica Guffanti, M.F. Alvisi, Alessia Anastasia et al. · British Journal of Cancer · 2021 · 40 citations · Full text

, , +16

Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial (NCT03921671)

Claudia Proto, M. Ganzinelli, Sara Manglaviti et al. · Annals of Oncology · 2024 · 31 citations · Full text

, , +14

1–5 of 12